Khaled Musallam/LinkedIn
Nov 20, 2025, 16:47
Khaled Musallam Takes on The Role as Chief of Cell/Gene Therapies and Hematology at Burjeel Cancer Institute
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Priviliged to be working with my friend Prof.Humaid Al-Shamsi to build on the strong foundations of BCI and lead the expansion of hematology services across the network, including dedicated programs in both classical (benign) and malignant hematology, and advanced cell and gene therapies through innovative clinical trials and strategic international partnerships with industry innovators.”
Stay updated with Hemostasis Today.
-
Jun 1, 2026, 15:24John Chuback: DVT Can Start With Symptoms Many People Brush Off
-
Jun 1, 2026, 15:20Venugopalan Unni: Guidelines for the Evaluation and Management of Acute Pulmonary Embolism in Adults
-
Jun 1, 2026, 15:10Smitirupa Mishra: Standardizing RBC Morphology Reporting – Why ICSH Guidelines Matter?
-
Jun 1, 2026, 14:54Davide Massimi: A Bloodless Approach to Third Space Endoscopy
-
Jun 1, 2026, 14:27Afshan Sumera: Plasma Proteomics Reveals Complement And Coagulation Disruption In Transfusion-Dependent Thalassemia
-
Jun 1, 2026, 13:44Milad Abdalla: Elevating Phlebotomy Standards – Why Order of Draw and Blood Cultures Matter
-
Jun 1, 2026, 13:39Abdul Mannan: The Moral Injury of Practising Haemato-Oncology in a Resource-Limited Setting
-
Jun 1, 2026, 13:34Filza Aslam: What Does a Patient Journey Partner Actually Do in Bleeding Disorders?
-
Jun 1, 2026, 13:33Darine Ghanem: Advancing Health Equity in Care at the LATAM Meeting